APOB and Insulin resistance: It remains important to note that, at the time of this study, the MHO subjects were healthier than their MUO peers based on measures of traditional cardiometabolic health risk, but it is unknown whether this discrepancy would remain stable over time or whether it may be extrapolated to other health domains (such as musculoskeletal, respiratory) or whether the inclusion of other indicators of cardiovascular health (e.g., apo B, inflammatory markers, insulin resistance) would impact the MHO prevalence estimates obtained in this study [12].